55 completed, 29 recruiting, 18 unknown, 13 active not recruiting. 134 Phase 3, 33 Phase 2.
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED) | Phase 3 | Not yet recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 219 | 2027-07-01 | 2026-06-04 |
| An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease BHV-1300 - Graves' Disease | Phase 2 / Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 356 | 2026-10-01 | 2026-10-28 |
| Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study MHB018A, MHB018A placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 84 | 2026-09-28 | 2026-10-14 |
| Treatment of Chronic Thyroid Eye Disease With MHB018A MHB018A injection, MHB018A injection Placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 135 | 2026-09-24 | 2026-10-14 |
| Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) linsitinib, Placebo - Thyroid Eye Disease, TED, Graves Orbitopathy | Phase 3 | Recruiting | Sling Therapeutics, Inc. | 130 | 2026-08-04 | 2026-10-20 |
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 60 | 2026-08-01 | 2026-07-23 |
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 117 | 2026-08-01 | 2026-07-23 |
| An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets. Desiccated Porcine Thyroid Extract Tablets - Hypothyroidism | Phase 3 | Recruiting | Neuvosyn Laboratories, LLC | 466 | 2026-06-30 | 2026-08-05 |
| Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease BHV-1300, Placebo - Graves Disease | Phase 3 | Recruiting | Biohaven Therapeutics Ltd. | 300 | 2026-06-26 | 2026-11-12 |
| Colchicine for Autoimmune and Subacute Thyroiditis colchicine, Prednisolone, NSAID - Hashimoto Thyroiditis, Subacute Thyroiditis | Phase 2 / Phase 3 | Recruiting | Mansoura University | 300 | 2026-06-15 | 2026-07-29 |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. efgartigimod PH20 SC, Placebo PH20 SC - Graves Disease | Phase 3 | Recruiting | argenx | 230 | 2026-06-10 | 2026-11-03 |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Efgartigimod PH20 SC, Placebo PH20 SC - Graves' Disease, Graves Disease | Phase 3 | Recruiting | argenx | 230 | 2026-06-10 | 2026-11-03 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| MHB018A Treatment in Patients With Chronic Thyroid Eye Disease MHB018A injection, MHB018A injection Placebo - Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 150 | 2026-03-17 | 2026-09-24 |
| Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED) | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 258 | 2026-01-09 | 2026-03-30 |
| A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease ZL-1109 (VRDN-003), Placebo - Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | Zai Lab (Shanghai) Co., Ltd. | 108 | 2025-12-05 | 2026-09-09 |
| Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC desiccated thyroid extract (DTE)+levothyroxine (L-T4) - Intermediate-to-High Risk Differentiated Thyroid Cancer | Phase 3 | Not yet recruiting | West China Hospital | 646 | 2025-11-30 | 2025-11-20 |
| A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease IBI311, Placebo - Thyroid Eye Disease | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 111 | 2025-09-10 | 2025-11-17 |
| MHB018A Treatment in Patients With Active Thyroid Eye Disease MHB018A, MHB018A placebo - Thyroid Associated Ophthalmopathies | Phase 3 | Active not recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 108 | 2025-07-22 | 2026-10-09 |
| A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) VRDN-003, Autoinjector - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 87 | 2025-07-01 | 2026-06-25 |
Showing 20 of 134. Sign in to see all of them.
Graves Ophthalmopathy (52) · Thyroid Neoplasms (32) · Graves Disease (18) · Hypothyroidism (10) · Hyperthyroidism (8) · Thyroid Cancer, Papillary (8) · Exophthalmos (6) · Adenocarcinoma, Follicular (4) · Dyslipidemias (4) · Hashimoto Disease (4) · Thyroid Carcinoma, Anaplastic (4) · Autoimmune Diseases (3) · Colorectal Neoplasms (3) · Euthyroid Sick Syndromes (3)
Endocrine System Diseases (132) · Immune System Diseases (68) · Goiter (64) · Eye Diseases (63) · Orbital Diseases (63) · Autoimmune Diseases (62) · Hyperthyroidism (60) · Exophthalmos (59) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (54) · Eye Diseases, Hereditary (52) · Genetic Diseases, Inborn (52) · Graves Disease (46) · Endocrine Gland Neoplasms (40) · Neoplasms (40)
Thyroxine (14) · Iodine-131 (8) · Methimazole (4) · Thyrotropin Alfa (4) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (3) · Methylprednisolone (3) · Propylthiouracil (3) · Sodium Chloride (3) · Triiodothyronine (3) · teprotumumab (3) · Antithyroid Agents (2) · Carbimazole (2) · Carboplatin (2) · Paclitaxel (2) · Prednisolone (2)
Viridian Therapeutics, Inc. (8) · Minghui Pharmaceutical (Hangzhou) Ltd (6) · Samsung Medical Center (5) · argenx (4) · Amgen (3) · Genzyme, a Sanofi Company (3) · Immunovant Sciences GmbH (3) · Innovent Biologics (Suzhou) Co. Ltd. (3) · Sling Therapeutics, Inc. (3) · Sun Yat-sen University (3) · Beijing Kanghong Biological Medicine Co., Ltd. (2) · Biohaven Therapeutics Ltd. (2) · Cancer Research UK (2) · Cantonal Hospital of St. Gallen (2) · Columbia University (2)
United States (43) · China (26) · Germany (24) · United Kingdom (23) · France (22) · Italy (22) · Spain (21) · Poland (18) · Canada (14) · South Korea (14) · Australia (11) · Austria (10) · Belgium (10) · Hungary (9) · Netherlands (8)
Mohsen B Kashkouli, MD (2) · Thomas Clerici, MD (2) · Agnieszka Adamska, Assoc.Prof. (1) · Ahmed Abdelal, MD (1) · Alan B Scott, MD (1) · Alexander McEwan, MB, MSc, MD, FRCP (1) · Amr A. El Sehrawy, MD, PhD, FRCPE (1) · Ana L Maia, MD, PhD (1) · Andreas Schuck, MD PhD (1) · Annamaria Colao (1) · Annie M Sawka, MD, PhD (1)
PMID 27797318, PMID 37786277, PMID 41066062, PMID 10634372, PMID 14652672, PMID 14668957, PMID 16400382, PMID 1802923, PMID 18382668, PMID 19322503, PMID 19850694, PMID 19865824, PMID 20126486, PMID 20505894, PMID 20632263, PMID 21834960, PMID 22025146, PMID 22551127, PMID 22551128, PMID 22753906, PMID 23009127, PMID 23984185, PMID 24002501, PMID 24015953, PMID 24731671, PMID 24768112, PMID 25343233, PMID 25563879, PMID 25671254, PMID 26074402, PMID 26088605, PMID 26195199, PMID 26370187, PMID 26426092, PMID 26670972, PMID 27272078, PMID 27521067, PMID 27548104, PMID 28237867, PMID 28249134, PMID 28562541, PMID 28960722, PMID 29045520, PMID 29396246, PMID 29807824, PMID 29942184, PMID 29951599, PMID 30055804, PMID 30471649, PMID 30501974
2023 (4), 2005 (2), 2017 (2), 2025 (2), 2009 (1), 2015 (1), 2019 (1), R01DK077814 (1), U10HD021410 (1), U10HD027860 (1), U10HD027869 (1), U10HD027915 (1), U10HD027917 (1), U10HD034116 (1), U10HD034136 (1)